Biopure Disclosure Policies To Be Reviewed Under Hemopure SEC Settlement
Biopure must undergo a review of its disclosure, compliance and other securities policies as part of a settlement with the Securities & Exchange Commission over alleged misrepresentations concerning its investigational synthetic blood product Hemopure
You may also be interested in...
FDA is questioning whether protocols for emergency research conducted without individual informed consent should be subjected to more public input
FDA Associate Commissioner for Regulatory Affairs John Taylor will serve as the liaison with the Securities & Exchange Commission as FDA expands its role in regulating investor communications
FDA's role in policing investor communications about regulatory actions will continue to receive attention in 2004 after the Securities & Exchange Commission opened investigations into Biopure and Amylin